PTC Therapeutics, Inc.
votoplam
Huntington's disease
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews votoplam for Huntington's disease around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 14h ago
“Novartis initiated global Phase 3 INVEST-HD study of votoplam”